News

October 17, 2019October 17, 2019

MG Outcome Measures Effectively Reflect Rapid Improvements After Plasma Exchange, Study Shows

News

Current patient- and physician-reported measures of disease severity and clinical response effectively reflect rapid improvements associated with plasma exchange in myasthenia gravis (MG) patients, a study reports. These findings support ... Read more

October 15, 2019October 15, 2019

UCB Buys Ra Pharma, Adding Zilucoplan to Its MG Pipeline

News

UCB will add the investigational candidate zilucoplan to its therapeutic pipeline for the treatment of people with myasthenia gravis (MG), after announcing it will acquire the therapy’s developer, Ra ... Read more

October 8, 2019October 8, 2019

NIH Grants $7.8M to Support Launch of Rare Disease Network for Myasthenia Gravis

News

The National Institutes of Health (NIH) awarded $7.8 million to researchers at George Washington University to launch a network for improving research, treatment, and education in myasthenia gravis. This ... Read more

October 3, 2019October 3, 2019

First Patient Dosed in Phase 3 Trial of Zilucoplan, Ra Pharma Announces

News

Ra Pharmaceuticals announced the first patient enrolled in RAISE, the company’s Phase 3 clinical trial assessing the effectiveness of zilucoplan as a therapy for generalized myasthenia gravis (gMG), has ... Read more

October 1, 2019October 1, 2019

Certain Medications and Smoking Cessation Can Protect Ocular MG From Becoming Generalized, Study Says

News

Treatment with immunosuppressive agents and Mestinon (pyridostigmine) protects against transition from ocular myesthenia gravis (MG) to a generalized form of the disease among patients with anti-acetylcholine receptor (AchR) antibodies, ... Read more

September 27, 2019September 27, 2019

NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC

News

Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board ... Read more

September 26, 2019September 26, 2019

DAS Therapeutics Acquires Full Rights to GT Biopharma’s Oral Therapy GTP-004

News

DAS Therapeutics has acquired GTP-004, an investigational oral treatment for myasthenia gravis, from GT Biopharma, the companies announced. GTP-004 will be named DAS-MG from now on, DAS Therapeutics said ... Read more

September 24, 2019September 24, 2019

Long-Term Use of Gabapentin May Trigger MG Exacerbations, Case Report Says

News

Physicians should keep in mind that severe exacerbations in patients with myasthenia gravis (MG) might be triggered by the use of gabapentin (sold under the brand name Neurontin, among ... Read more

September 12, 2019September 12, 2019

Diabetes Drug Metformin Reduces Clinical Severity of Myasthenia Gravis in Animal Study

News

The diabetes drug metformin, which is largely safe and minimally toxic, can be of therapeutical value for myasthenia gravis, according to a study conducted using a mouse model of ... Read more

September 10, 2019September 10, 2019

Recording Eye Movements May Help Diagnose MG Earlier, Study Suggests

News

Assessing altered eye movements with a technique called electrooculography (EOG) may become a non-invasive method for early diagnosis of myasthenia gravis (MG), according to new research. The study, “Analysis ... Read more

Pin It on Pinterest